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Abstract
Background: Previous studies of healthcare utilization for chronic obstructive pulmonary disease (COPD) have
focused on time-trends in COPD visits or COPD treatments, or the effect of hospital volume on mortality. Few data
are available regarding outcomes after an ED visit (and subsequent hospitalization) for COPD, which are both very
common in patients with COPD. Our objective was to assess time-trends and predictors of emergency department
and subsequent inpatient health care utilization and charges associated with COPD in the U.S.
Method: We used the 2009-12 U.S. Nationwide Emergency Department Sample (NEDS) to study the incidence of
ED visits and subsequent hospitalizations with COPD as the primary diagnosis. We used the 2012 NEDS data to
study key patient/hospital factors associated with outcomes, including charges, hospitalization and dischage from
hospital to home.
Results: ED visits for COPD as the primary diagnosis increased from 1.02 million in 2009 to 1.04 in 2010 to 1.10
million in 2012 (0.79–0.82 % of all ED visits); respective charges were $2.13, $2.32, and $3.09 billion. In 2012, mean
ED charges/visit were $2,812, hospitalization charges/visit were $29,043 and the length of hospital stay was 4.3 days.
49 % were hospitalized after an ED visit. Older age, higher median income, metropolitan residence and comorbidities
(diabetes, hypertension, HF, hyperlipidemia, CHD, renal failure and osteoarthritis) were associated with higher
risk whereas male sex, Medicaid or self pay insurance status, hospital location in Midwest, South or West U.S.
were associated with lower risk of hospitalization. 65.4 % of all patients hospitalized for COPD from ED were
discharged home. Older age, comorbidities (diabetes, HF, CHD, renal failure, osteoarthritis) and metropolitan
residence were associated with lower odds of discharge to home, whereas male sex, payer other than Medicare,
Midwest, South or West U.S. hospital location were associated with higher odds.
Conclusion: Health care utilization and costs in patients with COPD are significant and increasing. COPD constitutes
a major public health burden in the U.S. We identified risk factors for hospitalization, costs, and home discharge in
patients with COPD that will allow future studies to investigate interventions to potentially reduce COPD-associated
utilization.
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Background
Chronic obstructive pulmonary disease (COPD) is associated
with significant morbidity and health care costs worldwide
[1]. COPD is the third leading cause of mortality in the U.S.
and affects >12 million Americans [2, 3]. COPD was associ-
ated with $32 billion in costs in 2010 in the U.S. [4]. It fre-
quently leads to inability to work and mobility limitations
[5], which poses high societal economic burden [6]. COPD is
associated with significant decrements in quality of life [7],
worst in those with higher COPD disease severity [8, 9]. In
addition to clinical burden, the inability to work due to
COPD also poses high economic burden on both patients
and governments [6].
Acute exacerbations of COPD are associated with signifi-
cant morbidity, and decrements in quality of life [10, 11] and
lead to frequent ED visits and hospitalizations. Studies have
examined factors associated with hospitalization in patients
with COPD, mostly in single-center settings or small cohorts
[12–14]. One study using a nationally representative U.S.
sample found that EDs with higher COPD volume had lower
mortality and shorter hospital length of stay [15] compared
to those with a lower volume. A previous study using the
U.S. National Hospital Ambulatory Medical Care Survey
(NHAMCS) from 1993 to 2005 reported 0.6 million COPD
visits annually [16], consistent with the estimates reported
earlier using the National emergency Department (NEDS)
data [15].
Previous studies of COPD ED visits focused on time-
trends in visits [17], effect of hospital volume on mortal-
ity [15] and trends in treatment [16]. Few, if any data,
are available regarding outcomes after an ED visit for
COPD. A recent NEDS study comparing COPD with
other chronic conditions combined COPD and bronchi-
ectasis and did not provide separate data for COPD [17].
An older study estimated 1.5 million emergency depart-
ment visits in 2002 in the U.S. [18]. These Centers for
Disease Control and Prevention (CDC) data are 15-years
old. Thus, contemporary data related to ED and inpatient
burden due to COPD in the U.S. are needed, to better
understand the current COPD burden on the healthcare
system. Our objective was to examine the predictors and
estimates of ED and inpatient utilization due to COPD as
the primary diagnosis and post-hospitalization disposition,
using contemporary NEDS data.
Methods
Data source and study population
We used the discharge data from the Nationwide Emer-
gency Department Sample (NEDS), the largest, all-payer
U.S. emergency department [ED] database that contains a
20 % stratified sample of ED visits from across the U.S.,
provided by the Healthcare Cost and Utilization Project
(HCUP), Agency for Healthcare Research and Quality
[19, 20]. NEDS data is provided by the HCUP State
Emergency Department Databases (SEDD) and the State In-
patient Databases (SID) [19, 20] that capture the discharge
information on ED visits that do not result vs. that result in
an admission to the same hospital, respectively. As an ex-
ample, 950 U.S. hospitals from 30 states contributed data in
2012.
NEDS is publicly available. NEDS provides appropriate
weights to obtain weighted national estimates [20]. For this
study, we limited analyses to patients aged 18 and older with
an ED visit with COPD as the primary diagnosis. COPD-
related visits and hospitalizations were identified using the
International Classification of Diseases, ninth revision, Com-
mon Modification (ICD-9-CM) code of 491.xx, 492.xx and
496.xx, which have been previously shown to be valid [21].
NEDS contains event-level data but not unique identifiers
so that individuals may be represented by multiple visits in
any given year. The Institutional Review Board at the Univer-
sity of Alabama at Birmingham (UAB) approved the study.
Outcomes of interest
We examined the following outcomes of interest: (1) ED
discharge disposition (hospitalization vs.routine dis-
charge); (2) ED charges; (3) Inpatient discharge to home
(vs. other); (4) Duration of hospital stay; and (5) Total
charges (ED and inpatient).
Covariates
We examined patient and hospital characteristics as co-
variates. These included age, sex, insurance status, resi-
dence [urban vs. rural] and annual median household
income estimated using residential zip code. Hospital
characteristics included geographical region [Northeast,
Midwest, South and West], location in metropolitan or
non-metropolitan area, and whether the hospital is
teaching vs. non-teaching. For each visit in NEDS, up to
15 ICD-9-CM diagnostic codes, and nine ICD-9-CM
procedure codes are provided. We pre-specified certain
non-pulmonary comorbidities as potential predictors of
outcomes in patients with COPD as the primary reason
for ED visit/hospitalization. These comorbidities were
chosen due to their common occurrence (coronary heart
disease [CHD], heart failure [HF], diabetes, renal failure,
hyperlipidemia, hypertension, osteoarthritis [OA], gout).
Statistical analysis
We calculated summary statistics for key outcomes asso-
ciated with COPD-related ED-visits and COPD-related
hospitalizations across 2009 to 2012. The original 2011
Nationwide Emergency Department Sample (NEDS) in-
cluded duplicated records in the South and Midwest and
a corrected 2011 dataset was not available in amended
form for us to analyze. Therefore, most analyses for
time-trends used 2009, 2010 and 2012 data. We used
the 2012 NEDS data, as the most recent data available,
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to analyze whether patient and hospital factors were as-
sociated with outcomes of COPD-related ED visit, i.e.
ED visit with COPD as the primary diagnosis (charges;
hospital admission vs. not), COPD-related inpatient ad-
mission (length of stay; total charges) and disposition
after inpatient admission (discharge to nursing home,
total charges).
We examined patient- and hospital characteristics and
comorbidities (secondary diagnoses) as potential predictors
of these outcomes (see covariate section). We performed
multivariable-adjusted logistic regression (discharge dis-
position, length of hospital stay ≥2 days) or linear regres-
sion (charges, duration of hospitalization) using SAS
version 9.3 (SAS corporation, Cary, NC, USA). Sensitivity
analyses examined the log of hospital stay, hospital stay
when dichotomized at 2 days, and the log of total hospital
charges, since hospital stay and charges variables were
slightly more normal distributed when log-transformed
and to examine whether findings were robust or not. Sen-
sitivity models were also performed adding asthma as a
pulmonary comorbidity to main models, since it frequently
accompanies COPD.
Results
Clinical and demographic characteristics
The number of ED visits for COPD increased from 1.02
million in 2009 to 1.04 in 2010 to 1.10 in 2012 (Table 1).
There were similar proportions of patients across study
years who were female or lived in metropolitan area.
Across the study years, the primary payer, hospital re-
gion and teaching status were also similar (Table 1).
Table 1 Emergency department (ED) visits for COPD as the primary diagnosis in year 2009, 2010 and 2012 NEDS database
2009 NEDS 2010 NEDS 2012 NEDS
#COPD ED visits (% total) 1,019,276 (0.79) 1,039,825 (0.80) 1,100,378 (0.82)
Age, in years
Mean (SE) 65.99 (0.15) 65.82 (0.13) 65.49 (0.13)
Median (IQR) 65.88 (55.71, 75.70) 65.68 (55.52, 75.36) 65.04 (55.34, 74.82)
Sex
Female 561298 (55.13) 573,622 (55.17) 608,895 (55.34)
Patient location (residence)
Micropolitan/not metro 283,145 (27.95) 280,036 (27.07) 297,501 (27.13)
Metropolitan (large or small) 729,842 (72.05) 754,433 (72.93) 798,895 (72.87)
Median house hold income
1st quartile (< $38,999) 371,277 (37.46) 373,961 (36.88) 428,687 (39.81)
2nd quartile ($39,000 to $47,999) 307,056 (30.98) 302,423 (29.83) 295,576 (27.45)
3rd quartile ($48,000 to $62999) 198,385 (20.01) 206,248 (20.34) 219,078 (20.34)
4th quartile ($63,000 or more) 114,521 (11.55) 131,230 (12.94) 133,571 (12.40)
Primary payer
Medicare 643,010 (63.18) 652,143 (62.84) 692,608 (63.02)
Medicaid 137,000 (13.46) 146,288 (14.10) 163,123 (14.84)
Private insurance 142,543 (14.00) 139,120 (13.40) 128,603 (11.70)
Self-pay/no charge 71,418 (7.02) 768,75 (6.92) 84,873 (7.72)
Other 23,818 (2.34) 23,395 (0.49) 29,812 (2.71)
Hospital Region
Northeast 170,206 (16.70) 175,398 (16.87) 181,739 (16.52)
Midwest 250,323 (24.56) 261,053 (25.11) 268,176 (24.37)
South 457,795 (44.91) 446,524 (42.94) 498,801 (45.33)
West 140,952 (13.83) 156,850 (15.08) 151,661(13.78)
Teaching status of hospital
Metropolitan non-teaching or non-metro 730,087 (71.63) 721,206 (69.36) 742,700 (67.49)
Metropolitan teaching 289,189 (28.37) 318,619 (30.64) 357,679 (32.51)
IQR interquartile range, SE standard error
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The mean age for patients with COPD with ER visit in
2012 was 65.5 years, and 55 % were female (Table 1).
73 % lived in the metropolitan area, Medicare was the
primary payer for 63 % and 45 % of all COPD-
hospitalizations occurred in hospitals located in the
South (Table 1). The number of ED visits over time was
stable (Fig. 1a) and income varied significantly by region
(Fig. 1b), being lower in Southern US than other regions.
Utilization and charges for COPD-related visits
COPD ED visits were 0.79–0.82 % of all ED visits
(128.9 million, 129.0 million and 134.4 in 2009, 2010
and 2012) during the study period. The ED charges
for visits with COPD as the primary diagnosis were
$2.13, $2.32, and $3.09 billion in 2009, 2010, and
2012 respectively (Additional file 1: Appendix 1). The
total charges for ED and inpatient services in COPD pa-
tients who were admitted to the hospital with COPD as
the primary diagnosis were $12.5, $12.7, and $14.2 billion
in the respective years (Additional file 1: Appendix 1).
Total ED and inpatient charges with COPD diagnosis in
any position (primary or other) were $121 billion in 2012
(Additional file 1: Appendix 1).
Forty-nine percent were admitted to the hospital from
the ED. Of those hospitalized with COPD as the primary
diagnosis, 46 % were discharged to home (Additional file 1:
Appendix 2). Mean ED charges for ED visits with
COPD as primary diagnosis were $2,812 and mean total
charges for admitted patients in 2012 were $29,043.
Mean length of hospital stay was 4.3 days (Additional file 1:
Appendix 2). Outcomes by study year are shown in
Additional file 1: Appendix 2.
a. Total number of Ed visits over time by region









































Fig. 1 Distribution of the total number of ED visits (a) and of income categories (b) with COPD as the primary diagnosis by region of
residence.* Multivariable model adjusted for gender, race, Charlson score, beta-blockers, diuretics, ACE inhibitors and statins. X-axis represents
the respective age, gender and race category and the y-axis hazard ratio. Each column represents the hazard ratio for that patient characteristic.
Reference category is no allopurinol use (use = 0 days), marked by hashed line passing through the hazard ratio of 1.00. Error bars represent 95 %
confidence interval
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Predictors of ED charges and discharge disposition
Older age, male sex, residence in metropolitan area
and hospital location in Midwest, South or West U.S.
location, were each associated with higher charges for
ED visit for COPD in multivariable-adjusted analyses
(Additional file 1: Appendix 3).
In univariate analyses, several patient and hospital
characteristics and comorbidities were associated with
COPD-hospitalization after an ED visit (Additional file 1:
Appendix 4). In multivariable-adjusted analyses, older age,
higher median household income and metropolitan resi-
dence were associated with higher risk whereas male sex,
Medicaid or self pay insurance status and hospital location
in Midwest, South or Western U.S. were associated with
lower risk of hospitalization after an ED visit for COPD
(Table 2). Diabetes, hypertension, HF, hyperlipidemia,
CHD were associated with 1.2–2.3 fold higher odds, renal
failure with 3.1-fold and osteoarthritis with 5.0-fold odds
of hospitalization in patients with ED visit with COPD as
the primary diagnosis, respectively (Table 2).
Hospitalization disposition and predictors
In 2012, of all hospitalizations for COPD as the pri-
mary diagnosis, 65.4 % were discharged home, 13.4 %
to skilled nursing/intermediate facilities, 17.2 % to
home health care and 1.1 % died (Additional file 1:
Appendix 5). Multivariable-adjusted analyses showed
that older age and metropolitan residence were associated
with lower odds, whereas male sex, payer other than
Medicare, and Midwest, South or West U.S. hospital loca-
tion were associated with higher odds of discharge to
home (Table 3). Comorbidities except hyperlipidemia,
hypertension, and gout were associated with lower-odds
of discharge to home (Table 3); heart disease and osteo-
arthritis were not significantly associated. As expected, an
opposite direction for associations was noted in multivari-
able-adjusted analyses for discharge to skilled facilities
(Additional file 1: Appendix 6).
Length of hospital stay and charges
Multivariable-adjusted linear regression showed that older
age and metropolitan location were associated with longer
stay in patients hospitalized with COPD as the primary diag-
nosis whereas male sex, non-Medicare primary payer, hos-
pital location other than Northeast were associated with
shorter hospital stay (Table 4). Most comorbidities except
hyperlipidemia, gout and hypertension were associated with
longer hospital stay (Table 4); heart disease, diabetes and
osteoarthritis were not significantly associated.
In multivariable-adjusted analyses, older age, higher
income, metropolitan location, Western U.S. hospital
location, and the presence of renal failure, HF and diabetes
were associated higher total (ED+ inpatient) hospital charges
(Table 5). Male sex, non-Medicare primary payer, and a few
comorbidities were associated with lower hospital charges
(Table 5).
Sensitivity analyses examining the log of hospital stay
(Additional file 1: Appendix 7), hospital stay when dichot-
omized at 2 days (Additional file 1: Appendix 8), or log of
total hospital charges (Additional file 1: Appendix 9)
showed similar results as above.
Impact of co-existing asthma on outcomes
When the main multivariable-adjusted models were add-
itionally adjusted for the presence of asthma, we found that
the odds of hospital admission from ED were not increased,
0.91 (0.79, 1.05; p= 0.19), but odds of discharge to home
were higher, 1.43 (1.29, 1.59); p < 0.0001). Asthma was sig-
nificantly associated with longer duration of hospital stay in
those hospitalized, but hospital charges were not significantly
different: beta coefficients 0.29 (0.15, 0.43; p < 0.0001) and
947.4 (-658.9, 2553.6; p= 0.24).
Discussion
In this study using the NEDS, a U.S. representative national
sample, we studied utilization of ED and inpatient resources
with COPD as the primary diagnosis. We found that COPD
was associated with >1 million ED visits and over half a
million hospitalizations in 2012. Our estimates for the
overall number of ED visits and inpatient hospitalizations
related to COPD are similar to those reported in a study
that combined COPD and bronchiectasis [17]. A previous
study of trends in COPD treatment in the ED showed
higher concordance with treatment recommendations in
the recent years [16], indicating that quality of COPD care
in the ED may be improving over time. We also examined
factors associated with health resource utilization and
charges for ED and inpatient visits due to COPD. Several
findings merit further discussion.
First, we found that several sociodemographic, comorbid-
ity, and hospital factors were associated with the risk of
hospitalization among COPD patients who presented to ED
with COPD as the primary diagnosis. Previous studies have
focused on pulmonary function status and COPD medica-
tions as predictors of COPD hospitalization and associated
costs [22, 23], but did not examine socio-demographic and
hospital characteristics in detail. Our study examined these
key characteristics and made important observations.
We found that older age, median household income above
$48,000, metropolitan residence and the presence of comor-
bidities were each associated with higher risk of
hospitalization. The association of older age with higher risk
of COPD hospitalization is not surprising and confirms
earlier similar findings from studies of smaller sample
sizes [12, 24], now in a larger, representative U.S. sample.
The association of higher median household income
with a higher risk of COPD hospitalization/costs in
interesting and extends a similar finding from other
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chronic conditions [25, 26] to COPD. Since models were
adjusted for insurance type, the income effect is independ-
ent of insurance status and type. It is possible that income
reflects education level or health literacy level, both of
which might impact the risk of hospitalization. The as-
sociation of female sex with higher odds of COPD
Table 2 Predictors of hospital admission among patients presenting to ER with COPD as the primary diagnosis using logistic regression
Univariate Multivariable-adjusted
OR (95 % CI) P-value OR (95 % CI) P-value
Age
< 50 Ref Ref
50- <65 2.01 (1.92, 2.09) <0.0001 1.45 (1.38, 1.51) <0.0001
65- <80 3.42 (3.23, 3.61) <0.0001 1.67 (1.57, 1.77) <0.0001
≥ 80 4.95 (4.65, 5.27) <0.0001 1.90 (1.77, 2.03) <0.0001
Gender
Female (ref) Ref Ref
Male 0.98 (0.96, 1.00) 0.0309 0.91 (0.89, 0.93) <0.0001
Median household income
1st quartile (< $38,999) Ref Ref
2nd quartile ($39,000 to $47,999) 1.14 (1.06, 1.23) 0.0009 1.08 (1.00, 1.18) 0.0509
3rd quartile ($48,000 to $62999) 1.40 (1.29, 1.53) <0.0001 1.17 (1.07, 1.29) 0.0012
4th quartile ($63,000 or more) 2.08 (1.86, 2.33) <0.0001 1.45 (1.29, 1.63) <0.0001
Primary payer
Medicare (ref) Ref Ref
Medicaid 0.52 (0.49, 0.54) <0.0001 0.91 (0.86, 0.96) 0.0005
Private insurance 0.63 (0.60, 0.66) <0.0001 0.98 (0.93, 1.03) 0.4990
Self-pay/no charge 0.30 (0.28, 0.31) <0.0001 0.70 (0.66, 0.74) <0.0001
Other 0.63 (0.55, 0.72) <0.0001 1.04 (0.93, 1.15) 0.5203
Patient location (residence)
Micropolitan/not metropolitan Ref Ref
Metropolitan (large or small) 1.70 (1.54, 1.89) <0.0001 1.42 (1.27, 1.58) <0.0001
Hospital Region
Northeast Ref Ref
Midwest 0.54 (0.45, 0.64) <0.0001 0.60 (0.51, 0.71) <0.0001
South 0.66 (0.56, 0.79) <0.0001 0.80 (0.67, 0.95) 0.0106
West 0.58 (0.48, 0.69) <0.0001 0.63 (0.52, 0.76) <0.0001
Teaching status of hospital
Metropolitan non-teaching or non-metropolitan Ref Ref
Metropolitan teaching 1.34 (1.17, 1.53) <0.0001 1.14 (0.99, 1.30) 0.0687
Comorbidities
CHD (ref: no) 3.77 (3.55, 4.01) <0.0001 1.89 (1.80, 1.99) <0.0001
Hyperlipidemia (ref: no) 4.30 (3.98, 4.64) <0.0001 2.35 (2.19, 2.51) <0.0001
Renal failure (ref: no) 6.90 (6.33, 7.53) <0.0001 3.10 (2.83, 3.39) <0.0001
CHF (ref: no) 3.96 (3.73, 4.21) <0.0001 2.13 (2.02, 2.25) <0.0001
Gout (ref: no) 4.61 (4.08, 5.22) <0.0001 1.87 (1.64, 2.14) <0.0001
Diabetes (ref: no) 2.24 (2.14, 2.33) <0.0001 1.19 (1.15, 1.24) <0.0001
Hypertension (ref: no) 3.50 (3.31, 3.69) <0.0001 1.93 (1.84, 2.02) <0.0001
Osteoarthritis (ref: no) 6.83 (6.07, 7.67) <0.0001 5.02 (4.42, 5.70) <0.0001
CHD coronary heart disease, CHF congestive heart failure, COPD chronic obstructive pulmonary disease, Significant odds ratios are in bold
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Table 3 Predictors of discharge to home among patients hospitalized with COPD as the primary diagnosis using logistic regression
Univariate Multivariable-adjusted
OR (95 % CI) P-value OR (95 % CI) P-value
Age
< 50 Ref Ref
50- <65 0.72 (0.67, 0.77) <0.0001 0.83 (0.76, 0.90) <0.0001
65- <80 0.34 (0.31, 0.37) <0.0001 0.51 (0.46, 0.56) <0.0001
≥ 80 0.16 (0.14, 0.17) <0.0001 0.25 (0.23, 0.28) <0.0001
Gender
Female Ref Ref
Male 1.26 (1.22, 1.30) <0.0001 1.22 (1.18, 1.26) <0.0001
Median house hold income
1st quartile (< $38,999) Ref Ref
2nd quartile ($39,000 to $47,999) 0.95 (0.89, 1.01) 0.1216 1.03 (0.96, 1.10) 0.3935
3rd quartile ($48,000 to $62999) 0.81 (0.75, 0.89) <0.0001 0.97 (0.89, 1.06) 0.4857
4th quartile ($63,000 or more) 0.65 (0.59, 0.72) <0.0001 0.99 (0.89, 1.10) 0.8347
Primary payer
Medicare Ref Ref
Medicaid 2.36 (2.22, 2.52) <0.0001 1.30 (1.22, 1.39) <0.0001
Private insurance 2.84 (2.60, 3.10) <0.0001 1.89 (1.74, 2.06) <0.0001
Self-pay/no charge 6.73 (5.97, 7.59) <0.0001 3.01 (2.62, 3.45) <0.0001
Other 2.47 (2.13, 2.87) <0.0001 1.46 (1.23, 1.74) <0.0001
Patient location (residence)
Micropolitan/not metro Ref Ref
Metropolitan (large or small) 0.79 (0.73, 0.86) <0.0001 0.88 (0.81, 0.96) 0.0049
Hospital Region
Northeast Ref Ref
Midwest 1.55 (1.36, 1.76) <0.0001 1.29 (1.11, 1.49) 0.0007
South 1.76 (1.57, 1.97) <0.0001 1.52 (1.33, 1.73) <0.0001
West 1.83 (1.59, 2.11) <0.0001 1.65 (1.43, 1.90) <0.0001
Teaching status of hospital
Metropolitan non-teaching or non-metropolitan Ref Ref
Metropolitan teaching 0.92 (0.83, 1.02) 0.1040 0.99 (0.90, 1.10) 0.8999
Comorbidities
CHD (ref: no) 0.79 (0.77, 0.82) <0.0001 1.01 (0.98, 1.05) 0.5676
Hyperlipidemia (ref: no) 1.06 (1.03, 1.10) 0.0008 1.22 (1.18, 1.27) <0.0001
Renal failure (ref: no) 0.60 (0.57, 0.62) <0.0001 0.88 (0.85, 0.92) <0.0001
CHF (ref: no) 0.50 (0.48, 0.51) <0.0001 0.67 (0.65, 0.69) <0.0001
Gout (ref: no) 0.87 (0.80, 0.94) 0.0007 1.14 (1.04, 1.24) 0.0036
Diabetes (ref: no) 0.88 (0.85, 0.91) <0.0001 0.91 (0.88, 0.94) <0.0001
Hypertension (ref: no) 0.88 (0.85, 0.90) <0.0001 1.06 (1.03, 1.09) 0.0001
Osteoarthritis (ref: no) 0.84 (0.80, 0.89) <0.0001 0.96 (0.92, 1.01) 0.1430
Length of stay, in days 0.83 (0.83, 0.84) <0.0001 0.85 (0.84, 0.85) <0.0001
CHD coronary heart disease, CHF congestive heart failure, COPD chronic obstructive pulmonary disease, Significant odds ratios are in bold
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Table 4 Predictors of duration of hospital stay among patients with COPD who were admitted to the hospital after presenting to
ED with COPD as the primary diagnosis using linear regression
Univariate Multivariable-adjusted
B-estimate (95 % CI) P-value B-estimate (95 % CI) P-value
Age
< 50 Ref Ref
50- <65 0.52 (0.43,0.61) <0.0001 0.50 (0.40, 0.59) <0.0001
65- <80 1.00 (0.89,1.10) <0.0001 0.82 (0.70, 0.93) <0.0001
≥ 80 1.18 (1.06,1.31) <0.0001 0.85 (0.73, 0.98) <0.0001
Gender
Female Ref Ref
Male -0.28 (-0.34, -0.23) <0.0001 -0.29 (-0.34, -0.24) <0.0001
Median house hold income
1st quartile (< $38,999) Ref Ref
2nd quartile ($39,000 to $47,999) 0.00 (-0.10, 0.10) 0.9732 -0.03 (-0.12, 0.07) 0.5973
3rd quartile ($48,000 to $62999) 0.05 (-0.06, 0.15) 0.3623 -0.07 (-0.17, 0.03) 0.1951
4th quartile ($63,000 or more) 0.40 (0.20, 0.59) 0.0001 0.11 (-0.05, 0.28) 0.1895
Primary payer
Medicare (ref) Ref Ref
Medicaid -0.42 (-0.52, -0.32) <0.0001 -0.06 (-0.16, 0.04) 0.2685
Private insurance -0.52 (-0.61, -0.43) <0.0001 -0.26 (-0.34, -0.17) <0.0001
Self-pay/no charge -1.19 (-1.29, -1.09) <0.0001 -0.74 (-0.85, -0.64) <0.0001
Other -0.61 (-0.80, -0.42) <0.0001 -0.26 (-0.42, -0.10) 0.0013
Patient location (residence)
Micropolitan/not metro Ref Ref
Metro (large or small) 0.35 (0.23, 0.47) <0.0001 0.28 (0.15, 0.41) <0.0001
Hospital Region
Northeast Ref Ref
Midwest -0.79 (-1.02, -0.57) <0.0001 -0.67 (-0.89, -0.45) <0.0001
South -0.43 (-0.65, -0.21) 0.0001 -0.27 (-0.48, -0.07) 0.0103
West -0.80 (-1.03, -0.58) <0.0001 -0.76 (-0.98, -0.54) <0.0001
Teaching status of hospital
Metropolitan non-teaching or non-metropolitan Ref Ref
Metropolitan teaching 0.15 (0.01, 0.30) 0.0363 0.03 (-0.12, 0.18) 0.7276
Comorbidities
CHD (ref: no) 0.16 (0.10, 0.21) <0.0001 -0.03 (-0.09, 0.02) 0.2051
Hyperlipidemia (ref: no) -0.20 (-0.25, -0.14) <0.0001 -0.30 (-0.35, -0.25) <0.0001
Renal failure (ref: no) 0.51 (0.43, 0.58) <0.0001 0.26 (0.19, 0.33) <0.0001
CHF (ref: no) 0.84 (0.78, 0.90) <0.0001 0.73 (0.66, 0.79) <0.0001
Gout (ref: no) -0.02 (-0.17, 0.13) 0.8001 -0.24 (-0.39, -0.08) 0.0029
Diabetes (ref: no) 0.12 (0.06, 0.17) <0.0001 0.03 (-0.02, 0.08) 0.2479
Hypertension (ref: no) -0.00 (-0.06, 0.05) 0.9132 -0.15 (-0.21, -0.09) <0.0001
Osteoarthritis (ref: no) -0.01 (-0.10,0.09) 0.8771 -0.07 (-0.16, 0.03) 0.1554
CHD coronary heart disease, CHF congestive heart failure, COPD chronic obstructive pulmonary disease, Significant beta coefficients are in bold. A negative
coefficient indicates a shorter hospital stay and positive coefficient, a longer hospital stay
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Table 5 Predictors of total (ED and inpatient) hospital charges in patients with COPD who were admitted to the hospital after
presenting to ED with COPD as the primary diagnosis using linear regression
Univariate Multivariable-adjusted
B-estimate (95 % CI) P-value B-estimate (95 % CI) P-value
Age
< 50 Ref Ref
50- <65 3891.1 (2985.4, 4796.7) <0.0001 3117.53 (2219.7, 4015.4) <0.0001
65- <80 6652.1 (5449.1, 7855.1) <0.0001 4176.16 (2912.7, 5439.7) <0.0001
≥ 80 7109.4 (5582.7, 8636.1) <0.0001 2974.40 (1606.2, 4342.6) <0.0001
Gender
Female Ref Ref
Male -426.92 (-1051.0, 197.2) 0.1797 -665.99 (-1277.8, -54.2) <0.0001
Median household income
1st quartile (< $38,999) Ref Ref
2nd quartile ($39,000 to $47,999) 371.8 (-1261.3, 2005.0) 0.6550 -273.8 (-1882.1, 1334.5) 0.7383
3rd quartile ($48,000 to $62999) 4658.7 (2156.6, 7160.9) 0.0003 2250.3 (34.0, 4466.6) 0.0466
4th quartile ($63,000 or more) 7493.74 (3997.5, 10990.0) <0.0001 4614.2 (1284.2, 7944.2) 0.0067
Primary payer
Medicare (ref) Ref Ref
Medicaid -2014.3 (-3242.1, -786.4) 0.0013 -963.2 (-2007.8, 81.3) 0.0707
Private insurance -3725.8 (-4972.1, -2479.4) <0.0001 -2264.3 (-3574.4, -954.1) 0.0007
Self-pay/no charge -7134.2 (-8265.9, -6002.6) <0.0001 -4291.1 (-5496.3, -3085.8) <0.0001
Other -2313.6 (-4674.1, 47.0) 0.0547 -2427.7 (-4355.3, -500.1) 0.0136
Patient location (residence)
Micropolitan/not metro Ref Ref
Metro (large or small) 9681.5 (7392.3, 11970.6) <0.0001 8000.2 (5631.0, 10369.3) <0.0001
Hospital Region
Northeast Ref Ref
Midwest -5464.4 (-9760.8, 1168.1) 0.0127 -3131.5 (-7348.2, 1085.1) 0.1453
South 257.9 (-4333.9, 4849.7) 0.9122 3009.9 (-1643.7, 7663.6) 0.2046
West 17022.9 (11248.1, 22797.8) <0.0001 18103.3 (12310.9, 23895.8) <0.0001
Teaching status of hospital
Metropolitan non-teaching or non-metropolitan Ref Ref
Metropolitan teaching 181.7 (-3059.2, 3422.7) 0.9124 -461.9 (-3862.1, 2938.4) 0.7898
Comorbidities
CHD (ref: no) 2094.6 (1516.9, 2672.4) <0.0001 892.91 (347.7, 1438.1) 0.0014
Hyperlipidemia (ref: no) -1748.2 (-2335.2, -1161.2) <0.0001 -2162.7 (-2709.3, -1616.1) <0.0001
Renal failure (ref: no) 4756.1 (3906.7, 5605.5) <0.0001 2414.5 (1672.6, 3156.4) <0.0001
CHF (ref: no) 7385.2 (6410.1, 8360.3) <0.0001 6489.5 (5491.6, 7487.4) <0.0001
Gout (ref: no) -1128.9 (-2562.4, 304.6) 0.1225 -3127.6 (-4587.4, -1667.8) <0.0001
Diabetes (ref: no) 1474.4 (853.5, 2095.3) <0.0001 844.6 (247.4, 1441.7) 0.0056
Hypertension (ref: no) 329.1 (-310.1, 968.2) 0.3125 -674.9 (-1341.2, -8.53) 0.0471
Osteoarthritis (ref: no) -2524.4 (-3469.5, -1579.3) <0.0001 -2153.9 (-3023.9, -1283.9) <0.0001
CHD coronary heart disease, CHF congestive heart failure, COPD chronic obstructive pulmonary disease, Significant beta estimates are in bold
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hospitalization is consistent with a similar finding from
Danish population-based study of 1.5-fold higher risk
[27]. Medicaid or self-pay insurance status, hospital loca-
tion in Midwest, South or Western U.S. were associated
with lower risk of hospitalization after ED visit for COPD.
The regional differences may be related to region-specific
practices, differing severity of COPD and/or coexistent
comorbidities by region, distance to nearest medical cen-
ter etc. To our knowledge, our study is the one of the first
U.S. studies to comprehensively examine the association
of important socio-demographic, comorbidity and hospital
characteristics and factors with COPD-hospitalization.
Comorbidities were risk factors for COPD hospitali-
zations. Diabetes, hypertension, heart failure, hyperlip-
idemia, and CHD were each associated with 1.2–2.3
fold higher odds of COPD hospitalization. Previous
literature examining the association of comorbidities with
COPD admission is somewhat contradictory. Coronary
artery disease and diabetes mellitus were significant risk
factors for COPD admission in some studies [28, 29], but
other studies found no association of comorbidities with
COPD readmission [30–33]. Potential reasons for differ-
ences in findings of previous studies are differences in
comorbidities adjusted in the analyses, study settings,
and omission of important confounders in some stud-
ies. General interventions such as physical rehabilita-
tion can improve outcomes of patients hospitalized
with COPD [34]. Other specific interventions and
management strategies targeting these comorbidities
(diabetes, hypertension, HF, CHD etc.) in patients
with COPD might reduce COPD-associated inpatient
utilization.
We found that renal failure was associated with 3.1-
times higher odds and osteoarthritis with 5.0-fold higher
odds of hospitalization among COPD patients who pre-
sented to ED. To our knowledge, these findings are
novel. Renal failure has been previously associated with
higher mortality in hospitalized COPD patients, but risk
of hospitalization was not assessed [35–37]. Whether
the increased hospitalization risk is due to the presence
of renal failure or its worsening during the treatment of
COPD exacerbation with corticosteroids and antibiotics
in the ED, cannot be determined from our study. Similar
to our observation of $4,756 unadjusted higher total
charges in COPD patients with renal failure, a recent
study by Manino et al. reported that the average all-
cause total health-care costs from the index date to
360 days after the index date were highest for patients
with chronic kidney disease, by $41,288 [38]. Therefore,
future studies need to examine whether optimization of
renal function by adequate hydration, medication man-
agement and optimization of renal function during a
COPD flare and its treatment may help in reducing this
risk of COPD hospitalization.
Osteoarthritis is associated with significant disability [39],
loss of independence and higher health care utilization [40]
in general. Difficulty in ambulation and daily activities due
to concomitant osteoarthritis and associated frailty may
contribute to a higher risk of hospitalization in COPD pa-
tients who also have difficulty in breathing. Use of assistive
devices, exercises and self-management strategies reduce
disability in osteoarthritis [41–43]; newer methods such as
neuromuscular electrical stimulation may be helpful in
some patients [44, 45]. Future studies should examine if
early diagnosis and optimal treatment of osteoarthritis in
patients with COPD, focusing on inexpensive and com-
monly available non-surgical interventions for osteoarth-
ritis, can reduce the risk of COPD hospitalization.
As noted above, our study findings of the association of
various socio-demographic, comorbidity and hospital char-
acteristics with COPD-hospitalization add to the current
knowledge. Factors such as long term oxygen therapy, low
health status, poor health related quality of life and inad-
equate physical activity [22] and body mass index, airflow
obstruction, dyspnea, and exercise capacity (BODE) index
[46] are associated with COPD hospitalization, and can
predict hospital length of stay in and mortality in patients
with COPD [47–50]. Our study identified additional risk
factors for COPD hospitalization. This new knowledge can
help clinicians risk stratify COPD patients and target those
with poorest prognosis.
Another finding was that older age, diabetes, HF and
renal failure were associated with lower odds and male
sex with higher odds of discharge to home (vs. nursing
home/facilities) in hospitalized COPD patients. These
findings are not unexpected; however, we are unaware of
any studies with a representative U.S. sample that have
explored this aspect of COPD care. Thus, these findings
are novel. It remains to be seen whether optimization of
HF, renal failure, and diabetes in COPD patients who are
admitted to the hospital can increase the proportion dis-
charged to home vs. skilled facilities.
Study findings must be interpreted considering study
limitations. These findings are likely only applicable to
ED-associated hospitalizations, not all hospitalizations.
Due to the nature of NEDS database that captures
data at the encounter level, rather than patient level,
we are unable to examine risk factors for COPD read-
missions, which are of interest clinically and for
healthcare policy. We believe that at least some COPD
admissions are readmissions. NEDS database does not
link the ED visit to inpatient admission to another
hospital, and we would likely miss this relatively un-
common event, since linkages of ED to hospitalization
are at a hospital level. This underestimation is pos-
sible, but it is likely to be an uncommon or rare event.
NEDS does not provide disease severity variables to
adjust in the analyses, which can lead to residual
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confounding. Generalizability of findings to other coun-
tries may not be possible, since health care settings differ.
Detailed assessments of COPD medications and their
associations with COPD-related utilization would have
provided additional insights; however, these data were not
available in NEDs and this was beyond the scope of this
study.
Our study has several strengths. NEDS is the largest,
publically available U.S. sample of ED visits, therefore
the findings are representative of and applicable to the
U.S. population. We adjusted for several covariates
and confounders including patient and hospital char-
acteristics in patients with COPD to obtain unbiased
estimates.
Conclusions
In conclusion, in this study of 2009-2012 NEDS data of
patients presenting to the ED with COPD as the primary
diagnosis, we studied patient discharge disposition from
the ED and ED costs and for those admitted to the hos-
pital, length of hospital stay, discharge disposition and
costs. We found that older age, metropolitan residence
and comorbidities (diabetes, HF, CHD, renal failure
and osteoarthritis) were associated with higher risk of
hospitalization and lower odds of discharge to home.
Higher income was also associated with higher risk of
hospitalization. We also identified other patient char-
acteristics associated with hospital charges. Studies in
the future should examine whether interventions tar-
geting these modifiable factors can improve COPD
outcomes.
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